1. 35MO Number of IL-2 doses and clinical outcomes of tumor-infiltrating lymphocyte (TIL) cell therapy: Post hoc analysis of the C-144-01 trial of lifileucel in patients with advanced melanoma. (December 2022) Authors: Hassel, J.C.; Sarnaik, A.; Chesney, J.; Medina, T.; Hamid, O.; Thomas, S.; Wermke, M.; Domingo-Musibay, E.; Kirkwood, J.M.; Larkin, J.; Weber, J.S.; Arance Fernandez, A.M.; Rodriguez, J.F.; Thomas, I.; Corrie, P.G.; Gontcharova, V.; Wu, X.; Shi, W.; Kluger, H. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 8 STUDY OF DIFFERENTIALLY EXPRESSED GENES IN LEIOMYOMATA AS COMPARED TO NORMAL MYOMETRIUM. (1st January 2006) Authors: Medina, T.; Richer, J.; Horwitz, K. Journal: Journal of investigative medicine Issue: Volume 54:Number 1(2006) Page Start: S81 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗